foxo4-dri nct FOXO4-DRI: Human Trial Status, Cancer
FOXO4 DRI: Human Trial Status, Cancer Research & Senolytic Data FOXO4 DRI Peptide 10 mg eXoZymes (Nasdaq: EXOZ) is targeting metabolic dysfunction a layer deeper than appetite. In a recent Webull webinar, Chief Commercial Officer Damien Perriman walked investors through NCT, the FOXO4 DRI 10MG Raw Amino
Pay in 4 interest-free payments of $6.12 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 30 - Aug 4


